New drug combination for recurrent head and neck cancer
Part of Cancer clinical trials.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosis of locally recurrent head and neck squamous cell carcinoma (cancer that returned in the original area) that can be surgically removed
- No prior chemotherapy or immunotherapy for the recurrent disease (though prior treatment for initial advanced cancer is okay if more than 6 months have passed)
- Good overall health with ECOG performance status 0 or 1 (able to carry out daily activities with minimal or no assistance)
- Normal blood counts, liver, kidney, heart, and thyroid function
- No active autoimmune diseases, active infections, uncontrolled high blood pressure or diabetes, or recent heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two newer drugs (one targeted therapy, one immunotherapy) given before surgery to shrink mouth cancer and improve outcomes. The goal is to see if combining them is safe and effective for people with stage III-IVA disease.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.